Chugai Pharmas Actemra gets Japanese approval for additional indication of SARS-CoV-2 pneumonia
By, Admin1 min read
Share
Chugai Pharmaceutical Co., Ltd. announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the humanized anti-human IL-6 receptor monoclonal antibody,
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
